Related Experiment Video
Updated: Jul 18, 2026
An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
Published on: October 20, 2017
Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats
Jun-Xian Yu1, Xiao-Xing Yin, Jian-Ping Shen
1Department of Pharmacology, Nanjing Medical University, Nangjing, PR China.
Abstract:
1. Diabetic neuropathy is a many faceted complication of both type I and II diabetes. The aim of the present study was to investigate the effects of bendazac lysine (BDL), an anticataract drug, on experimental diabetic peripheral neuropathy (DPN) in rats. 2. Diabetes was induced in rats by intraperitoneal injection of 75 mg/kg streptozotocin (STZ) dissolved in 0.1 mol/L citrate buffer (pH 4.4). Bendazac lysine was administered to rats at doses of 50, 100 and 200 mg/kg twice a day for 12 weeks. 3. Diabetic rats without treatment showed hypopraxia, polydipsia, polyuria, slow weight gain, cataract, increased tail-flick threshold temperature, decreased motor nerve conduction velocity (nd induced pathological morphological changes of myelinated nerve fibres. All these symptoms were ameliorated in diabetic rats treated with BDL. Bendazac lysine ameliorated the blood glucose concentration, glycosylated haemoglobin levels and insulin levels in the plasma of diabetic rats, reduced aldose reductase activity in erythrocytes and advanced glycation end-products in both nerves and serum and increase the activity of glutathione peroxidase in the nerves and Na(+)/K(+)-ATPase in the nerves and erythrocytes. 4. Bendazac lysine exerts its protective effects against the progression of diabetic peripheral neuropathy in STZ-diabetic rats through multiple mechanisms and is a potential drug for the prevention of deterioration in DPN.
Insights
Bendazac lysine (BDL) shows promise in treating diabetic peripheral neuropathy (DPN). This anticataract drug improved nerve function and reduced diabetes-related complications in rats, suggesting a potential therapeutic role.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Diabetic peripheral neuropathy (DPN) is a significant complication of type I and II diabetes.
- Existing treatments for DPN have limitations, necessitating the exploration of novel therapeutic agents.
Purpose of the Study:
- To investigate the efficacy of bendazac lysine (BDL), an anticataract drug, in ameliorating experimental diabetic peripheral neuropathy (DPN) in a rat model.
- To explore the underlying mechanisms by which BDL may exert protective effects against DPN progression.
Main Methods:
- Diabetes was induced in rats using streptozotocin (STZ).
- Bendazac lysine (BDL) was administered at varying doses (50, 100, 200 mg/kg) twice daily for 12 weeks.
- Neurological, biochemical, and pathological parameters were assessed to evaluate treatment effects.
Main Results:
- BDL treatment significantly ameliorated symptoms of DPN, including improved nerve conduction velocity and reduced nerve fiber damage in STZ-diabetic rats.
- BDL administration normalized blood glucose, glycosylated hemoglobin, and insulin levels, while reducing aldose reductase activity and advanced glycation end-products.
- The drug increased the activity of protective enzymes like glutathione peroxidase and Na(+)/K(+)-ATPase in nerve tissues and erythrocytes.
Conclusions:
- Bendazac lysine (BDL) demonstrates significant protective effects against the progression of diabetic peripheral neuropathy in a rat model.
- BDL acts through multiple mechanisms, including antioxidant and anti-glycation pathways, to prevent nerve damage.
- BDL is a potential therapeutic agent for preventing the deterioration of DPN in diabetic patients.
